ClinicalTrials.gg
Not yet recruitingNCT07951281Updated Nov 20, 2026

Performance of Lumetry for Arterial Carbon Dioxide (paCO2) Assessment and Chronic Obstructive Pulmonary Disease (COPD) Screening

An interventional study of lumetry and Arterialized Capillary Blood Gas Analysis in Pulmonary Disease, Chronic Obstructive and Hypercapnia, sponsored by Lumetry Diagnostics GmbH. Not yet recruiting at 1 site in Austria. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Lumetry Diagnostics GmbH · Not applicable, Interventional, and Diagnostic

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Not applicable
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 96 studies in Pulmonary Disease, Chronic Obstructive with a site in Austria — 14 open to participants now, 20 under way, 3 of them phase 3. Pulmonary Disease, Chronic Obstructive · Austria.

Planned enrollment
43rd of 83
300 · median 304
Started
2026
with 1 other
No phase
19 of 96
6 open now
Primary completion
2027-12
later than 14 of 19 live
Registered
96th of 96
by date

Among the 96 studies in Pulmonary Disease, Chronic Obstructive with a site in Austria, this one is the 43rd largest by planned enrollment of the 83 interventional ones that give a count, is one of 2 that started in 2026, is one of 19 with no phase, reaches primary completion later than 14 of the 19 other live ones, and was the 96th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

14 of the 96 studies in Pulmonary Disease, Chronic Obstructive with a site in Austria are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 96 studies in Pulmonary Disease, Chronic Obstructive with a site in Austria, or all of them as a file.
02

Study summary

The purpose of this clinical study is to evaluate how well the lumetry device performs in two areas: estimating the level of carbon dioxide in the arterial blood (paCO2) and screening for chronic obstructive pulmonary disease (COPD).

lumetry is a small handheld device that analyzes exhaled breath. Participants breathe normally into the device for 60 seconds. No forced or maximal breathing maneuvers are required for the lumetry measurement.

Today, the carbon dioxide level in the blood is usually measured with a blood gas analysis, which requires a blood sample. COPD is usually diagnosed with spirometry, a lung function test that requires maximal breathing effort and trained staff.

In this study, adults with COPD of different severity and adults without known lung disease each attend a single study visit. All participants perform one lumetry breath measurement and a standard lung function test (forced spirometry). Participants with COPD also give a small capillary blood sample from the earlobe for blood gas analysis, and some of them additionally have their carbon dioxide level measured through the skin (transcutaneous measurement). By comparing the lumetry results with these established methods, the study assesses how accurately the device estimates the carbon dioxide level in the blood. By comparing the lumetry COPD screening result with spirometry and the confirmed clinical diagnosis, the study assesses how reliably the device distinguishes between people with and without COPD.

The study is conducted at one hospital in Vienna, Austria, and will include 300 participants.

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive
  • Hypercapnia

Keywords

  • COPD
  • Hypercapnia
  • Prediction
  • lumetry
  • Lumetry Diagnostics
  • Blood Gas Analysis
  • Blood Gas Monitoring, Transcutaneous
  • End-Tidal Carbon Dioxide
  • Carbon Dioxide Partial Pressure Determination
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • Age between 18 and 90 years
  • Diagnosed (COPD), stages GOLD I to IV, or no known lung function pathologies
  • Able to sit upright for the duration of the procedure without exhaustion
  • Women of : not breastfeeding and either a negative pregnancy test prior to the start of the investigation or use of a reliable method of (intrauterine device or oral contraceptive pill) throughout the investigation. Women of childbearing potential are defined as women who have not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) and are not (at least 12 months of amenorrhea in a woman over the age of 50 in the absence of other biological or physiological causes).

Exclusion criteria

Exclusion Criteria:

  • Considered by the investigator to be inappropriate for inclusion or unlikely to comply with the requirements of the study
  • Lung disease other than (e.g., asthma); participants with asthma-COPD overlap may be included
  • Previously documented chronic heart failure with an below 40%
  • Mental or physical inability to comply with time schedules and study procedures
  • Current participation in a clinical study that may affect breathing behaviour (medicinal product or medical device), or participation within 30 days prior to screening
  • Prior participation in this clinical investigation
  • Possible or confirmed pregnancy, or breastfeeding
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Participants With and Without COPD

    Adults with chronic obstructive pulmonary disease (COPD), stratified by severity (50 GOLD I/II, 50 GOLD III, 50 GOLD IV), and 150 adults without known lung function pathologies. All participants perform a single 60-second lumetry measurement of normal resting breathing, followed by forced spirometry. Participants with COPD additionally undergo arterialized capillary blood gas analysis, with a subgroup of 50 participants with COPD (GOLD III and IV) additionally undergoing transcutaneous carbon dioxide monitoring.

    Device: lumetry · Diagnostic Test: Arterialized Capillary Blood Gas Analysis · Diagnostic Test: Transcutaneous Carbon Dioxide Monitoring · Diagnostic Test: Forced Spirometry

Interventions

  • Devicelumetry

    Handheld capnography and spirometry device that estimates the arterial partial pressure of carbon dioxide (paCO2) and provides a COPD screening result from a single 60-second measurement of normal resting breathing. The device also provides the end-tidal carbon dioxide value (petCO2), which serves as comparator for the paCO2 estimate.

  • Diagnostic testArterialized Capillary Blood Gas Analysis

    Capillary blood sample from the arterialized earlobe, collected immediately after the lumetry measurement. Reference standard for paCO2. Performed in participants with COPD only.

  • Diagnostic testTranscutaneous Carbon Dioxide Monitoring

    Non-invasive measurement of carbon dioxide through the skin (tcPCO2), recorded as close in time as possible to the lumetry measurement and blood sampling. Comparator for paCO2 estimation. Performed in a subgroup of 50 participants with COPD.

  • Diagnostic testForced Spirometry

    Standard lung function test performed at the end of the study visit in all participants. Together with the documented clinical diagnosis, reference standard for the COPD screening result.

06

What researchers measure

Primary outcomes

  1. Difference in Mean Absolute Deviation From Blood Gas paCO2 Between lumetry-Estimated paCO2 and End-Tidal Carbon Dioxide (petCO2)

    In participants with chronic obstructive pulmonary disease (COPD), the carbon dioxide level in the arterial blood (paCO2) estimated by lumetry is compared with the value measured in a capillary blood sample (blood gas analysis, reference standard). The average size of the difference, regardless of direction (mean absolute deviation), is calculated for lumetry and for the standard breath-based value (end-tidal carbon dioxide, petCO2). The outcome is the MAD of petCO2 minus the MAD of lumetry, so a positive value means lumetry is closer to the blood gas value.

    Time frame: Day 1 (single study visit)

  2. Sensitivity of the lumetry COPD Screening Result

    Percentage of participants with COPD, as established by forced spirometry and documented clinical diagnosis (reference standard), who are classified as positive by the lumetry COPD screening result.

    Time frame: Day 1 (single study visit)

  3. Specificity of the lumetry COPD Screening Result

    Percentage of participants without COPD, as established by forced spirometry and documented clinical diagnosis (reference standard), who are classified as negative by the lumetry COPD screening result.

    Time frame: Day 1 (single study visit)

Secondary outcomes

  1. Standard Deviation of the Differences Between lumetry-Estimated paCO2 and Blood Gas paCO2

    In participants with chronic obstructive pulmonary disease (COPD), the difference between the lumetry-estimated arterial carbon dioxide level (paCO2) and the paCO2 measured by capillary blood gas analysis (reference standard) is calculated for each participant. The outcome is the standard deviation of these differences, describing the precision of the lumetry estimate. Unit: millimeters of mercury (mmHg).

    Time frame: Day 1 (single study visit)

  2. Percentage of lumetry paCO2 Estimates Within 8 mmHg of Blood Gas paCO2

    In participants with COPD, the percentage of lumetry paCO2 estimates that differ by 8.0 millimeters of mercury (mmHg) or less in either direction from the paCO2 measured by capillary blood gas analysis (reference standard).

    Time frame: Day 1 (single study visit)

  3. Difference in Mean Absolute Deviation From Blood Gas paCO2 Between lumetry-Estimated paCO2 and Transcutaneous Carbon Dioxide (tcPCO2)

    In a subgroup of 50 participants with COPD, the average size of the difference, regardless of direction (mean absolute deviation), from the paCO2 measured by capillary blood gas analysis (reference standard) is calculated for lumetry and for transcutaneous carbon dioxide monitoring (tcPCO2). The outcome is the difference between these two averages. Unit: millimeters of mercury (mmHg).

    Time frame: Day 1 (single study visit)

Other outcomes

  1. Number of Participants With Adverse Events, Adverse Device Effects, or Device Deficiencies

    Number of participants with at least one adverse event, adverse device effect, or device deficiency related to the study procedures, recorded during the study visit.

    Time frame: Day 1 (single study visit)

  2. Cross-Validated Sensitivity of a Re-Trained lumetry COPD Screening Algorithm

    Exploratory analysis. Sensitivity of a re-trained version of the lumetry machine learning algorithm for identifying participants with chronic obstructive pulmonary disease (COPD), estimated by stratified repeated k-fold cross-validation using the study data. Reference standard: forced spirometry and documented clinical diagnosis.

    Time frame: Day 1 (single study visit)

  3. Cross-Validated Specificity of a Re-Trained lumetry COPD Screening Algorithm

    Exploratory analysis. Specificity of a re-trained version of the lumetry machine learning algorithm for identifying participants without COPD, estimated by stratified repeated k-fold cross-validation using the study data. Reference standard: forced spirometry and documented clinical diagnosis.

    Time frame: Day 1 (single study visit)

  4. Cross-Validated Mean Absolute Deviation of Re-Trained lumetry paCO2 Estimates From Blood Gas paCO2

    Exploratory analysis. Average size of the difference, regardless of direction (mean absolute deviation), between the arterial carbon dioxide level (paCO2) estimated by a re-trained version of the lumetry machine learning algorithm and the paCO2 measured by capillary blood gas analysis, estimated by stratified repeated k-fold cross-validation in participants with COPD. Unit: millimeters of mercury (mmHg).

    Time frame: Day 1 (single study visit)

07

Study locations

1 site
08

References and documents

Publications

  • Klemm et al. Predicting arterial pCO2 using capnographic recordings - A pilot study using a novel breath analysis device. Eur Respir J. 2025; 66(Suppl 69): PA2529. doi:10.1183/13993003.congress-2025.PA2529

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2027, 12 months later.

Of 88 industry-sponsored interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 35. This study's planned 12 months is below that.

Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2026
First posted
Nov 20, 2026
StartEst.
Dec 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07951281
Lead sponsor
Lumetry Diagnostics GmbH
Collaborators
Klinik Floridsdorf, Karl Landsteiner Institute for Lung Research and Pneumological Oncology
Responsible party
Sponsor
First posted
Nov 20, 2026
Start date
Dec 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 20, 2026

Study contacts

Ruth Masih, MSc Biotechnology
Contact
ruth.masih@lumetry.at
+4366488262391
Nejla Hidic, BSc Biomedical Engineering
Contact
nejla.hidic@lumetry.at
+4366488262391
Arschang Valipour, Prim. Priv. -Doz. Dr.
principal investigator · Klinik Floridsdorf, Department of Respiratory and Critical Care Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion